NCT06994572 - Study of CT-01 as Monotherapy and Combination Therapy in Subjects With Intermediate or Advanced Hepatocellular Carcinoma | Biotech Hunter

Enrollment

141

Participants

Timeline

Start Date

May 26, 2025

Primary Completion Date

April 16, 2029

Study Completion Date

April 1, 2030

Conditions

Hepatocellular Carcinoma (HCC)

Interventions

DRUG

CT-01

Investigational small-molecule degrader targeting transcription factors in HCC. Used as monotherapy or with everolimus in dose-escalation/expansion settings. Specific to protocol CT-01-CD-1.

DRUG

EVEROLIMUS

Approved mTOR inhibitor used in combination with CT-01 for HCC in this study. Evaluated for safety, tolerability, and PK/PD in CT-01-CD-1 protocol.